A Randomized Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Randomized Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2015

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 132 to 140 and additional trial locations (France, United Kingdom) added as reported by European Clinical Trials Database.
    • 21 May 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
    • 21 May 2010 Planned end date changed from 1 Nov 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top